Takeda Pharmaceutical Company Limited (TAKEDA) cash flow statement
JPX · Healthcare · Drug Manufacturers - Specialty & Generic · 47,029 employees · CEO Julie So-Young Kim
- Price
- ¥6,651.00 +2.78%
- Market cap
- ¥10.6T
- Enterprise value
- ¥14.8T
- Last report
- Q2 '26 filed 2026-09-30
- Next report
- 2027-01-28 EPS est. ¥88.42
In Q2 '26 Takeda Pharmaceutical Company Limited (TAKEDA) generated ¥258B of operating cash flow, invested ¥55.7B in capital expenditure and kept ¥213B of free cash flow. Over the last four quarters free cash flow was ¥588B.
Cash flow
| Cash flow | Trend | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||||||
| Net income | ¥106B | -¥3.02B | ¥95.2B | ¥92B | ¥23.8B | -¥103B | ¥124B | -¥11.7B | ¥104B | -¥24.3B | ¥113B | ¥192B | |
| Depreciation & amortization | ¥187B | ¥187B | ¥192B | ¥192B | ¥187B | ¥190B | ¥182B | ¥185B | ¥191B | ¥164B | ¥163B | ¥164B | |
| Stock-based compensation | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 | ¥18.7B | ¥17.8B | ¥0 | ¥18.2B | ¥0 | |
| Deferred income tax | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 | ¥39.9B | ¥30.1B | ¥0 | ¥0 | ¥0 | |
| Change in working capital | -¥139B | ¥99.1B | -¥190B | -¥80.5B | ¥126B | ¥74.9B | -¥120B | ¥21.9B | ¥10B | -¥213B | -¥159B | -¥34.7B | |
| Other non-cash items | -¥32.9B | -¥10.3B | ¥61.9B | ¥55B | ¥15.7B | ¥30.1B | ¥18.1B | ¥124B | -¥3.63B | ¥114B | -¥8.14B | -¥64.2B | |
| Operating cash flow | ¥121B | ¥272B | ¥159B | ¥259B | ¥352B | ¥192B | ¥204B | ¥378B | ¥349B | ¥40.4B | ¥128B | ¥258B | |
| Investing | |||||||||||||
| Capital expenditure | -¥77.1B | -¥64.3B | -¥138B | -¥60.7B | -¥56.7B | -¥92.7B | -¥75.1B | -¥40.1B | -¥41.6B | -¥63.3B | -¥53.8B | -¥55.7B | |
| Acquisitions | ¥267M | -¥13.7B | ¥2.95B | ¥5.42B | ¥1.27B | ¥11B | ¥35.7B | ¥417M | ¥3.36B | ¥569M | ¥0 | ¥12.6B | |
| Purchases of investments | -¥2.46B | -¥2.04B | -¥13B | -¥14.8B | -¥67.6B | -¥3.18B | -¥215M | -¥1.55B | -¥14.9B | -¥738M | ¥0 | -¥200M | |
| Sales / maturities of investments | ¥458M | ¥6.93B | ¥5.32B | ¥17.8B | ¥3.56B | ¥60.5B | ¥1.13B | ¥2.88B | ¥1.56B | ¥1.46B | ¥0 | ¥17B | |
| Other investing | ¥63M | -¥3.92B | -¥18.7B | -¥27.8B | -¥628M | ¥399M | ¥186M | -¥9.79B | -¥183B | -¥1.16B | -¥33.9B | ¥698M | |
| Investing cash flow | -¥78.8B | -¥77.1B | -¥161B | -¥80B | -¥120B | -¥24B | -¥38.3B | -¥48.1B | -¥235B | -¥63.2B | -¥87.7B | -¥25.6B | |
| Financing | |||||||||||||
| Net debt issued / repaid | ¥35.2B | ¥57B | ¥441B | -¥57.1B | -¥460B | -¥146B | ¥12.2B | ¥36.6B | -¥23M | -¥15B | -¥11.3B | -¥240B | |
| Share buybacks | ¥0 | ¥0 | -¥1.88B | ¥0 | ¥0 | -¥50B | -¥51.6B | ¥0 | ¥0 | ¥0 | -¥1.01B | ¥0 | |
| Dividends | -¥138B | -¥9.13B | -¥138B | -¥9.2B | -¥145B | -¥9.74B | -¥145B | -¥8.79B | -¥149B | -¥8.79B | -¥150B | -¥7.73B | |
| Other financing (incl. tax on vested shares) | ¥34.3B | -¥84.4B | ¥31.3B | -¥16.9B | -¥14.7B | -¥61.6B | -¥13.5B | -¥39.7B | -¥13.6B | -¥14.4B | -¥17.9B | -¥12.8B | |
| Financing cash flow | -¥68.8B | -¥36.5B | ¥332B | -¥83.2B | -¥620B | -¥267B | -¥198B | -¥12B | -¥163B | -¥38.2B | -¥180B | -¥260B | |
| Summary | |||||||||||||
| FX effect on cash | -¥3.11B | -¥242B | ¥269B | -¥41B | ¥22.9B | -¥161B | ¥149B | ¥13.4B | ¥22.4B | ¥1.1B | ¥6.36B | -¥14.6B | |
| Net change in cash | -¥29.7B | -¥83.2B | ¥599B | ¥54.7B | -¥365B | -¥260B | ¥116B | ¥331B | -¥26.5B | -¥59.9B | -¥134B | -¥42.4B | |
| Free cash flow (OCF - capex) | ¥73.9B | ¥228B | ¥102B | ¥210B | ¥307B | ¥143B | ¥156B | ¥325B | ¥307B | -¥6B | ¥73.8B | ¥213B | |
| Interest paid | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 | ¥15.6B | ¥0 | |
| Cash flow | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||||
| Net income | ¥115B | ¥187B | ¥135B | ¥44.2B | ¥376B | ¥230B | ¥317B | ¥144B | ¥108B | ¥192B | |
| Depreciation & amortization | ¥171B | ¥182B | ¥248B | ¥584B | ¥560B | ¥583B | ¥664B | ¥728B | ¥761B | ¥721B | |
| Change in working capital | ¥42B | ¥34.2B | -¥5.36B | ¥117B | ¥314B | ¥140B | -¥114B | -¥264B | -¥69.5B | -¥250B | |
| Other non-cash items | -¥68.3B | -¥23.6B | -¥74.9B | -¥190B | -¥344B | ¥68B | ¥9.84B | ¥31.8B | ¥163B | ¥276B | |
| Operating cash flow | ¥260B | ¥380B | ¥303B | ¥555B | ¥905B | ¥1.02T | ¥877B | ¥640B | ¥962B | ¥939B | |
| Investing | |||||||||||
| Capital expenditure | -¥112B | -¥128B | -¥134B | -¥218B | -¥236B | -¥186B | -¥634B | -¥481B | -¥348B | -¥411B | |
| Acquisitions | -¥522B | ¥59.7B | -¥2.82T | ¥469B | ¥577B | -¥19.7B | ¥8.92B | -¥4.74B | ¥20.6B | ¥39.8B | |
| Purchases of investments | -¥82.1B | -¥88.7B | -¥17.1B | -¥7.55B | -¥12.6B | -¥8.34B | -¥10.2B | -¥6.77B | -¥98.5B | -¥16.5B | |
| Sales / maturities of investments | ¥75.3B | ¥40.7B | ¥65B | ¥49.4B | ¥74.6B | ¥16.9B | ¥22.3B | ¥8.02B | ¥87.1B | ¥7.91B | |
| Other investing | -¥20.4B | ¥13B | ¥64.3B | -¥14.1B | -¥10.3B | -¥7.33B | -¥3.05B | -¥4B | -¥46.7B | -¥8.04B | |
| Investing cash flow | -¥661B | -¥103B | -¥2.84T | ¥279B | ¥392B | -¥204B | -¥616B | -¥488B | -¥385B | -¥388B | |
| Financing | |||||||||||
| Net debt issued / repaid | ¥471B | -¥153B | ¥3.16T | -¥556B | -¥656B | -¥561B | -¥242B | ¥116B | -¥222B | ¥43.8B | |
| Share buybacks | -¥23.1B | -¥18.8B | -¥1.17B | -¥3.74B | -¥2.14B | -¥77.5B | -¥26.9B | -¥2.33B | -¥51.9B | -¥51.6B | |
| Dividends | -¥142B | -¥142B | -¥143B | -¥283B | -¥283B | -¥284B | -¥279B | -¥287B | -¥302B | -¥312B | |
| Other financing (incl. tax on vested shares) | -¥9.75B | -¥4.08B | -¥36.2B | -¥35.6B | -¥39.4B | -¥40.1B | -¥52.6B | -¥80.7B | -¥61.8B | -¥55.8B | |
| Financing cash flow | ¥297B | -¥318B | ¥2.98T | -¥878B | -¥981B | -¥962B | -¥601B | -¥254B | -¥638B | -¥375B | |
| Summary | |||||||||||
| FX effect on cash | -¥27.5B | ¥16.8B | -¥31.4B | -¥21.1B | ¥12.5B | ¥28.8B | -¥281B | ¥77.6B | ¥89.9B | ¥186B | |
| Net change in cash | -¥132B | -¥24.9B | ¥408B | -¥64.5B | ¥329B | -¥117B | -¥620B | -¥24.4B | ¥28.6B | ¥361B | |
| Free cash flow (OCF - capex) | ¥198B | ¥313B | ¥225B | ¥428B | ¥794B | ¥898B | ¥737B | ¥465B | ¥762B | ¥763B | |
Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in JPY.
Operating cash flow, capex, free cash flow
quarterlyUses of cash vs operating cash flow
fiscal yearsShare count and EPS
quarterly, dilutedThe other statements
Sources
Statements, segment revenue, metrics and estimates: Financial Modeling Prep.
Data as of 2026-11-01